E-course: Adjuvant therapy for RCC from the perspective of the EAU RCC Guidelines Panel
Offering adjuvant pembrolizumab is now the standard of care in patients who are at risk of relapse after surgery. This e-course organised by the European School of Urology (ESU) and the EAU Guidelines Office will provide you with crucial information on the treatment.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
In this e-course, you will:
- Discover the basis for the recommendation.
- Learn about optimising patient selection.
- Gain insights into how to discuss the treatment with patients.
- Know more about the impact of adjuvant use of pembrolizumab on overall therapy management.
Leading experts will also provide essential updates on adjuvant immune checkpoint inhibitor therapy in renal cell cancer (RCC).
Join the e-course now and strengthen your knowledge in managing relapse in patients treated with adjuvant pembrolizumab.
Speakers:
- Prof. A. Bex (GB)
- Prof. Dr. J. Bedke (DE)
- Prof. Dr. T. Powles (GB)
- Dr. V. Grünwald (DE)
This e-course is brought to you in collaboration with the EAU Guidelines Office.